Table 1.
Baseline clinical characteristics of all patients and their univariate correlations with overall survival.
| Clinical characteristics | No. (%) | HR | 95%CI | P-value |
|---|---|---|---|---|
| Gender | ||||
| Female Male |
43 (24.3) 134 (75.7) |
Ref. 1.46 |
0.96–2.24 |
0.07 |
| Age | ||||
| Median (1st – 3rd Qu) | 65.9 (60.1–73.5) | 1.01 | 0.99–1.03 | 0.16 |
| KPS | ||||
| <80 ≥80 |
36 (20.3) 141 (79.7) |
Ref. 0.55 |
0.37–0.83 |
0.004 • |
| Smoking status | ||||
| No Yes |
6 (3.3) 171 (96.7) |
Ref. 3.99 |
0.96–16.19 |
0.06 |
| Clinical AJCC Stage | ||||
| I II III |
35 (19.8) 23 (13.0) 119 (67.2) |
Ref. 2.25 1.58 |
1.21–4.14 0.99–2.52 |
0.01 • 0.05 |
| T stage | ||||
| 1 2 3 4 |
41 (23.2) 43 (24.3) 49 (27.7) 44 (24.8) |
Ref. 1.33 1.47 1.35 |
0.79–2.21 0.9–2.41 0.88–2.37 |
0.27 0.12 0.14 |
| N stage | ||||
| 0 1 2 3 |
59 (33.3) 20 (11.3) 61 (34.5) 27 (20.9) |
Ref. 1.52 1.47 1.58 |
0.83–2.76 0.97–2.23 0.98–2.357 |
0.17 0.07 0.06 |
| Chemotherapy | ||||
| No Yes |
60 (33.9) 117 (66.1) |
Ref. 1.21 |
0.84–1.74 |
0.3 |
| SBRT | ||||
| No | 152 (85.9) | Ref. | ||
| Yes | 25 (24.1) | 0.49 | 0.26–0.91 | 0.02 • |
| BED (Gy) | ||||
| Low Median (1st – 3rd Qu) High Median (1st – 3rd Qu) |
78.0 (72.0–79.7) 105.0 (92.3–109.9) |
Ref. 0.56 |
0.4–0.8 |
0.001 • |
Abbreviation: KPS, Karnofsky Performance Status; SBRT, Stereotactic Body Radiation Therapy; BED, Biologically Effective Dose; Qu, quartile; HR, hazard ratio; CI, confident interval.
• P-value < 0.05.